aon glp-1 Weight Loss Drugs: A Point of View for Professional Service Firms in the U.S., UK, and Canada GLP-1 Studio Podcast | Podcast

FOR CHRONIC KIDNEY DISEASE SOURCE: National Kidney Foundation

Narrative reviews discuss that high pricing, insurance exclusions, and concerns about the appropriateness of prescribing may reinforce existing disparities and stigma [89]

Reporting incidents and suspected counterfeit products is essential for continuously monitoring drug safety and usefulness

With recent FDA enforcement against misleading direct-to-consumer prescription drug advertising, telehealth and DTC platforms that advertise GLP-1 products will likely need more careful legal / regulatory oversight of their ad claims, especially around benefit claims and safety disclosures

Most include educational resources, side effect management guides, and lifestyle coaching as part of their service packages